The gut microbiome mediates metabolic health through multiple mechanisms, including its role in naturally stimulating GLP-1 production. Akkermansia muciniphila and other next-generation strains are on the forefront of microbiome research, touted for their potential to improve metabolic health. Learn from Adam Perlman, MD, MPH, about the emerging science on the gut-metabolism axis and how to support the gut microbiome in clinical practice to optimize metabolic health.
Learning Objective #1: Learn the mechanisms by which the gut microbiome mediates metabolic health.
Learning Objective #2: Understand how the gut-metabolism axis plays a critical role in natural GLP-1 production.
Learning Objective #3: Learn how to incorporate Akkermansia-based probiotics into clinical practice.
Dr. Adam Perlman is the Chief Medical Officer at Pendulum Therapeutics. He is the former Director of Integrative Health and Wellbeing for Mayo Clinic, Florida as well as Medical Director for Employee Wellbeing on the Florida campus. Dr. Perlman has served as the Associate Vice President for Health and Wellness for the Duke University Health System and the Executive Director for Duke Integrative Medicine. He is past Chair for the Academic Consortium for Integrative Medicine and Health, comprising over 75 leading academic medical centers in North America. Prior to his work with Duke, Dr. Perlman was at the University of Medicine and Dentistry of New Jersey, now Rutgers University. There, he held the Hunterdon Endowed Professorship in Complementary and Alternative Medicine and was Chair for the Department of Primary Care within the School of Health Related Professions.
Dr. Perlman received his BA from Tufts University and his MD from Boston University School of Medicine, completing residencies in Internal Medicine and Preventive Medicine as well as a General Internal Medicine Research Fellowship at Boston Medical Center. He earned an MPH from the Boston University School of Public Health.